SNP Profiling for Prostate Cancer Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective approaches for predicting prostate cancer risk, aggressiveness, and treatment outcomes, particularly in African American men, due to insufficient understanding of molecular mechanisms and genetic disparities.
Innovation Solution
Genetic profiling to identify specific single nucleotide polymorphisms (SNPs) in genes such as TP63, MET, WNT1, ALDH1A1, and EGFR, which indicate increased or decreased risk and aggressiveness of prostate cancer, enabling improved diagnosis and treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current general prostate cancer screening methods are used, then broad population coverage is achieved, but prediction accuracy for cancer risk and aggressiveness is insufficient
Solution Approach 1:
The patent segments the general prostate cancer screening approach into specific genetic sub-profiles by identifying and analyzing particular SNP markers (such as those in the 8q24 region, HOXB13, and other susceptibility loci). This segmentation allows for more precise risk stratification and aggressiveness prediction while maintaining a manageable diagnostic framework through focused genetic testing panels.
Solution Approach 2:
The patent applies local quality by targeting specific genetic regions and SNP markers that are known to be associated with prostate cancer risk and aggressiveness. Rather than analyzing the entire genome uniformly, the method focuses on locally identified high-risk genetic regions, thereby improving prediction accuracy while limiting the complexity to only the most relevant genetic markers.
2Reliability
If genetic profiling of multiple SNPs is performed, then personalized risk assessment improves, but detection complexity and cost increase
Solution Approach 1:
The patent implements partial action by selecting and analyzing only a specific subset of SNP markers that have been statistically validated to provide the most predictive value for prostate cancer risk and aggressiveness. This selective approach achieves reliable personalized risk assessment without requiring comprehensive analysis of all possible genetic variants, thereby controlling detection complexity while maintaining high reliability.
Solution Approach 2:
The patent changes the parameter of detection by transitioning from general phenotypic screening to specific genotypic analysis of predetermined SNP markers. This parameter change enables more accurate risk stratification through objective genetic data while standardizing the detection process to a fixed panel of markers, thus improving reliability without proportionally increasing complexity.
3Measurement precision
If racial and ethnic disparities in prostate cancer are addressed through targeted studies, then prediction accuracy for specific populations improves, but generalizability of findings may be limited
Solution Approach 1:
The patent applies local quality by identifying SNP markers and genetic risk profiles that are specific to different racial and ethnic populations. The method tailors the genetic profiling approach to population-specific genetic characteristics, thereby improving prediction accuracy for each group while maintaining a unified framework that can be adapted across different populations through selective application of relevant markers.
Data Source
AI summary
The present disclosure provides biomarkers for the identification of prostate cancer and methods of use. The present disclosure also provide biomarkers that can be used for determining risk of developing prostate cancer, aggressiveness of prostate cancer and survival rate for subpopulations of African American males or non-Hispanic white males.